| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
INCY
Incyte
|
Jun 15, 2026 | HOLD |
Strong Buy
+1.0% avg upside
47 analysts
|
— | -2.9% |
|
CNTX
Context Therapeutics
|
Jun 15, 2026 | BUY |
Strong Buy
+873.3% avg upside
12 analysts
|
— | · |
|
GMAB
Genmab
|
Jun 15, 2026 | BUY |
Buy
+38.3% avg upside
26 analysts
|
— | · |
|
CLYM
Climb Bio
|
Jun 11, 2026 | BUY |
Strong Buy
+57.9% avg upside
18 analysts
|
— | · |
|
EVMN
Evommune, Inc.
|
Jun 10, 2026 | BUY |
Strong Buy
+134.6% avg upside
12 analysts
|
— | -2.1% |
|
CGEM
Cullinan Management
|
Jun 08, 2026 | BUY |
Strong Buy
+125.7% avg upside
15 analysts
|
— | +8.7% |
|
AUTL
Autolus Therapeutics
|
Jun 02, 2026 | BUY |
Strong Buy
+605.8% avg upside
16 analysts
|
— | -16.6% |
|
JBIO
Jade Biosciences
|
Jun 01, 2026 | BUY |
Strong Buy
+232.9% avg upside
16 analysts
|
— | -9.5% |
|
JSPR
Jasper Therapeutics
|
Jun 01, 2026 | HOLD |
Strong Buy
+6361.2% avg upside
17 analysts
|
— | -11.8% |
|
UPB
Upstream Bio, Inc.
|
May 19, 2026 | BUY |
Strong Buy
+514.9% avg upside
9 analysts
|
— | -19.7% |
|
INSM
Insmed
|
May 18, 2026 | BUY |
Strong Buy
+82.2% avg upside
36 analysts
|
— | -8.1% |
|
KROS
Keros Therapeutics
|
May 14, 2026 | HOLD |
Strong Buy
+139.0% avg upside
21 analysts
|
— | -4.5% |
|
TENX
Tenax Therapeutics
|
May 12, 2026 | BUY |
Strong Buy
+213.9% avg upside
8 analysts
|
— | +1.6% |
|
JANX
Janux Therapeutics Inc
|
May 08, 2026 | BUY |
Strong Buy
+217.1% avg upside
21 analysts
|
$14.00
1.63% Downside
|
-0.2% |
|
IMA
ImageneBio
|
May 08, 2026 | BUY |
Strong Buy
+179.6% avg upside
12 analysts
|
— | +7.4% |
|
ARGX
Argenx Se
|
May 07, 2026 | BUY |
Strong Buy
-15.8% avg upside
46 analysts
|
— | +12.1% |
|
NAMS
NewAmsterdam Pharma Company
|
May 07, 2026 | BUY |
Strong Buy
+56.4% avg upside
18 analysts
|
— | -14.4% |
|
XNCR
Xencor
|
May 06, 2026 | BUY |
Buy
+159.9% avg upside
27 analysts
|
$13.00
2.77% Upside
|
-13.4% |
|
CMPX
Compass Therapeutics
|
May 05, 2026 | BUY |
Strong Buy
+373.4% avg upside
19 analysts
|
— | +3.6% |
|
AMGN
Amgen
|
May 01, 2026 | BUY |
Buy
-11.6% avg upside
57 analysts
|
— | +3.1% |
|
BMY
Bristol-Myers Squibb
|
Apr 30, 2026 | HOLD |
Buy
+9.1% avg upside
42 analysts
|
— | -10.9% |
|
ABBV
AbbVie
|
Apr 29, 2026 | BUY |
Buy
+2.9% avg upside
43 analysts
|
$203.00
6.19% Downside
|
+8.5% |
|
AXSM
Axsome Therapeutics
|
Jan 03, 2026 | BUY |
Strong Buy
-10.5% avg upside
28 analysts
|
— | +46.9% |
|
IONS
Ionis Pharmaceuticals
|
Oct 11, 2025 | BUY |
Strong Buy
+13.3% avg upside
43 analysts
|
$116.76
57.46% Upside
|
+3.8% |
|
DNTH
Dianthus Therapeutics
|
Sep 13, 2025 | BUY |
Strong Buy
+8.8% avg upside
29 analysts
|
— | +122.7% |
|
INKT
MiNK Therapeutics
|
Aug 29, 2025 | HOLD |
Strong Buy
+81.2% avg upside
6 analysts
|
— | -20.7% |
|
AGEN
Agenus
|
Aug 29, 2025 | HOLD |
Strong Buy
+164.7% avg upside
17 analysts
|
— | -14.3% |
|
VRTX
Vertex Pharmaceuticals
|
Jun 28, 2025 | BUY |
Strong Buy
-2.6% avg upside
61 analysts
|
— | +3.1% |
|
MRNA
Moderna
|
Jun 07, 2025 | HOLD |
Hold
+6.1% avg upside
38 analysts
|
— | +68.6% |
|
TPST
Tempest Therapeutics
|
Apr 25, 2025 | HOLD |
Buy
+1669.9% avg upside
18 analysts
|
— | -76.9% |
|
NCNA
Nucana
|
Apr 25, 2025 | HOLD |
Buy
+559.7% avg upside
9 analysts
|
— | -98.1% |
|
IMUX
Immunic
|
Mar 29, 2025 | BUY |
Strong Buy
+166.0% avg upside
21 analysts
|
$1.20
91.54% Downside
|
+0.0% |
|
RNTX
Rein Therapeutics
|
Dec 29, 2022 | HOLD |
Strong Buy
+1064.9% avg upside
5 analysts
|
— | +63.1% |
|
PVLA
Palvella Therapeutics
|
Jan 03, 2022 | BUY |
Strong Buy
+45.3% avg upside
27 analysts
|
— | · |
|
ATRA
Atara Biotherapeutics
|
Dec 07, 2021 | BUY |
Buy
+79.6% avg upside
18 analysts
|
— | -74.0% |
|
ATNM
Actinium Pharmaceuticals
|
Nov 19, 2021 | BUY |
Strong Buy
+633.5% avg upside
11 analysts
|
— | +56.6% |
|
BIIB
Biogen
|
Jul 23, 2021 | BUY |
Strong Buy
+25.1% avg upside
51 analysts
|
— | -36.6% |
|
NKTR
Nektar Therapeutics
|
Jun 11, 2021 | BUY |
Strong Buy
+16.5% avg upside
25 analysts
|
— | -81.2% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.